Development of nanoparticulate systems with action in breast and ovarian cancer: nanotheragnostics

References

• Wang X, Wang Y, Chen ZG, et al. Advances of cancer therapy by nanotechnology. Cancer Res Treat. 2009;41:1–11.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–760.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818–1822.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986;46:6387–6392.
   PubMed Web of Science ®Google Scholar
• Khawar IA, Kim JH, Kuh H-JJ. Improving drug delivery to solid tumors: priming the tumor microenvironment. J Control Release. 2015;201:78–89.
   PubMed Web of Science ®Google Scholar
• Tomasina J, Lheureux S, Gauduchon P, et al. Nanocarriers for the targeted treatment of ovarian cancers. Biomaterials. 2013;34:1073–1101.
   PubMed Web of Science ®Google Scholar
• Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Heal. 2016;4:e609–e616.
   PubMed Web of Science ®Google Scholar
• Perinotto AC, Caseli L, Hayasaka CO, et al. Dendrimer-assisted immobilization of alcohol dehydrogenase in nanostructured films for biosensing: ethanol detection using electrical capacitance measurements. Thin Solid Films. 2008;516:9002–9005.
   Web of Science ®Google Scholar
• Blanco E, Hsiao A, Mann AP, et al. Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci. 2011;102:1247–1252.
   PubMed Web of Science ®Google Scholar
• Caruso F, Hyeon T, Rotello VM. Nanomedicine. Chem Soc Rev. 2012;41:2537–2538.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7:1041–1053.
   PubMed Web of Science ®Google Scholar
• Saif MW. U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane(R)) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer. JOP. 2013;14:686–688.
   PubMedGoogle Scholar
• Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol. 1996;36:55–63.
   PubMed Web of Science ®Google Scholar
• Monneret C. Platinum anticancer drugs. From serendipity to rational design. Ann Pharm Fr. 2011;69:286–295.
   PubMedGoogle Scholar
• Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev. 2012;64:1394–1416.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24:1–16.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3:16–20.
   PubMed Web of Science ®Google Scholar
• Fan Z, Fu PP, Yu H, et al. Theranostic nanomedicine for cancer detection and treatment. J Food Drug Anal. 2014;22:3–17.
   PubMed Web of Science ®Google Scholar
• Boulaiz H, Alvarez PJ, Ramirez A, et al. Nanomedicine: application areas and development prospects. Int J Mol Sci. 2011;12:3303–3321.
   PubMed Web of Science ®Google Scholar
• Kranz C, Eaton DC, Mizaikoff B. Analytical challenges in nanomedicine. Anal Bioanal Chem. 2011;399:2309–2311.
   PubMed Web of Science ®Google Scholar
• Venditto VJ, Szoka FC. Cancer nanomedicines: so many papers and so few drugs! Adv Drug Deliv Rev. 2013;65:80–88.
   PubMed Web of Science ®Google Scholar
• Korsmeyer R. Critical questions in development of targeted nanoparticle therapeutics. Regen Biomater. 2016;3:143–147.
   PubMed Web of Science ®Google Scholar
• Zhan C, Li C, Wei X, et al. Toxins and derivatives in molecular pharmaceutics: drug delivery and targeted therapy. Adv Drug Deliv Rev. 2015;90:101–118.
   PubMed Web of Science ®Google Scholar
• WHO. Breast cancer [Internet]. World Health Organization; 2018 [cited 2018 Aug 21]. Available from: http://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/#.W3v30DwIPRA.mendeley.
   Google Scholar
• Cedolini C, Bertozzi S, Londero AP, et al. Type of breast cancer diagnosis, screening, and survival. Clin Breast Cancer. 2014;14:235–240.
   PubMed Web of Science ®Google Scholar
• Juhascik MP, Negrusz A, Faugno D, et al. An estimate of the proportion of drug-facilitation of sexual assault in four U.S. localities. J Forensic Sci. 2007;52:1396–1400.
   PubMed Web of Science ®Google Scholar
• Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14:9–32.
   PubMed Web of Science ®Google Scholar
• Kujawa KA, Lisowska KM. [Ovarian cancer – from biology to clinic]. Postepy Hig Med Dosw. (Online). 2015;69:1275–1290.
   PubMedGoogle Scholar
• Dong X, Men X, Zhang W, et al. Advances in tumor markers of ovarian cancer for early diagnosis. Indian J Cancer. 2014;51 Suppl 3:e72–e76.
   PubMedGoogle Scholar
• Meinhold-Heerlein I, Fotopoulou C, Harter P, et al. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet. 2016;293:695–700.
   PubMed Web of Science ®Google Scholar
• Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol. 2006;107:1399–1410.
   PubMed Web of Science ®Google Scholar
• Goldberg JM, Piver MS, Jishi MF, et al. Age at onset of ovarian cancer in women with a strong family history of ovarian cancer. Gynecol Oncol. 1997;66:3–9.
   PubMed Web of Science ®Google Scholar
• Gharpure KM, Wu SY, Li C, et al. Nanotechnology: future of oncotherapy. Clin Cancer Res. 2015;21:3121–3130.
   PubMed Web of Science ®Google Scholar
• Vieira DB, Gamarra LF. Advances in the use of nanocarriers for cancer diagnosis and treatment. Einstein (São Paulo). 2016;14:99–103.
   PubMed Web of Science ®Google Scholar
• Baetke SC, Lammers T, Kiessling F. Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol. 2015;88:1–12.
   Web of Science ®Google Scholar
• He C, Lin W. Hybrid nanoparticles for cancer imaging and therapy. Cancer Treat Res. 2015;166:173–192.
   PubMedGoogle Scholar
• Zhao J, Lee P, Wallace MJ, et al. Gold nanoparticles in cancer therapy: efficacy, biodistribution, and toxicity. Curr Pharm Des. 2015;21:4240–4251.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53:283–318.
   PubMed Web of Science ®Google Scholar
• Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012;2:3–44.
   PubMed Web of Science ®Google Scholar
• Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm. 2011;8:2101–2141.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Fessi H, Elaissari A. Theranostic applications of nanoparticles in cancer. Drug Discov Today. 2012;17:928–934.
   PubMed Web of Science ®Google Scholar
• Rizzo LY, Theek B, Storm G, et al. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol. 2013;24:1159–1166.
   PubMed Web of Science ®Google Scholar
• Mohanraj V, Chen Y, Chen M&. Nanoparticles – a review. Trop J Pharm Res Trop J Pharm Res. 2006;5:561–573.
   Google Scholar
• Solanki A, Kim JD, Lee K-B. Nanotechnology for regenerative medicine: nanomaterials for stem cell imaging. Nanomedicine (Lond). 2008;3:567–578.
   PubMed Web of Science ®Google Scholar
• Cancino J, Marangoni VS, Zucolotto V. Nanotechnology in medicine: concepts and concerns. Quim Nova. 2014;37:521–526.
   Web of Science ®Google Scholar
• Jain PK, ElSayed IH, El-Sayed MA. Au nanoparticles target cancer. Nano Today. 2007;2:18–29.
   Web of Science ®Google Scholar
• Anikeeva P, Deisseroth K. Photothermal genetic engineering. ACS Nano. 2012;6:7548–7552.
   PubMed Web of Science ®Google Scholar
• Lee J, Chatterjee DK, Lee MH, et al. Gold nanoparticles in breast cancer treatment: promise and potential pitfalls. Cancer Lett. 2014;347:46–53.
   PubMed Web of Science ®Google Scholar
• Sperling RA, Rivera Gil P, Zhang F, et al. Biological applications of gold nanoparticles. Chem Soc Rev. 2008;37:1896.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang J, Li X, et al. Selective inhibition of breast cancer stem cells by gold nanorods mediated plasmonic hyperthermia. Biomaterials. 2014;35:4667–4677.
   PubMed Web of Science ®Google Scholar
• Oldenburg S, Averitt R, Westcott S, et al. Nanoengineering of optical resonances. Chem Phys Lett. 1998;288:243–247.
   Web of Science ®Google Scholar
• Madani SY, Naderi N, Dissanayake O, et al. A new era of cancer treatment: carbon nanotubes as drug delivery tools. Int J Nanomedicine. 2011;6:2963–2979.
   PubMed Web of Science ®Google Scholar
• Shi Kam NW, O’Connell M, Wisdom JA, et al. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci. 2005;102:11600–11605.
   PubMed Web of Science ®Google Scholar
• Liu Z, Chen K, Davis C, et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008;68:6652–6660.
   PubMed Web of Science ®Google Scholar
• Ilinskaya AN, Dobrovolskaia MA. Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology. Nanomedicine. 2013;8:773–784.
   PubMed Web of Science ®Google Scholar
• Li Z, Kawashita M, Araki N, et al. Magnetite nanoparticles with high heating efficiencies for application in the hyperthermia of cancer. Mater Sci Eng C. 2010;30:990–996.
   Web of Science ®Google Scholar
• Jabir NR, Tabrez S, Ashraf GM, et al. Nanotechnology-based approaches in anticancer research. Int J Nanomedicine. 2012;7:4391–4408.
   PubMed Web of Science ®Google Scholar
• Sutradhar KB, Amin ML. Nanotechnology in cancer drug delivery and selective targeting. ISRN Nanotechnol. 2014;2014:1–12.
   Google Scholar
• Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86:215–223.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhang L, Song Y, et al. Hierarchical targeted hepatocyte mitochondrial multifunctional chitosan nanoparticles for anticancer drug delivery. Biomaterials. 2015;52:240–250.
   PubMed Web of Science ®Google Scholar
• Basile L, Pignatello R, Passirani C. Active targeting strategies for anticancer drug nanocarriers. Curr Drug Deliv. 2012;9:255–268.
   PubMed Web of Science ®Google Scholar
• Thierry B. Drug nanocarriers and functional nanoparticles: applications in cancer therapy. Curr Drug Deliv. 2009;6:13.
   Google Scholar
• Shi J, Kantoff PW, Wooster R, et al. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20–37.
   PubMed Web of Science ®Google Scholar
• Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131–135.
   PubMed Web of Science ®Google Scholar
• Chen YC, Lo CL, Lin YF, et al. Rapamycin encapsulated in dual-responsive micelles for cancer therapy. Biomaterials. 2013;34:1115–1127.
   PubMed Web of Science ®Google Scholar
• Tabatabaei Rezaei SJ, Nabid MR, Niknejad H, et al. Multifunctional and thermoresponsive unimolecular micelles for tumor-targeted delivery and site-specifically release of anticancer drugs. Polymer. 2012;53:3485–3497.
   Web of Science ®Google Scholar
• Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79.
   PubMed Web of Science ®Google Scholar
• R Khan D. The use of nanocarriers for drug delivery in cancer therapy David R. Khan. J Cancer Sci Ther. 2010;02:058–062.
   Google Scholar
• Qian WY, Sun DM, Zhu RR, et al. pH-sensitive strontium carbonate nanoparticles as new anticancer vehicles for controlled etoposide release. Int J Nanomedicine. 2012;7:5781–5792.
   PubMed Web of Science ®Google Scholar
• Kaur S, Prasad C, Balakrishnan B, et al. Trigger responsive polymeric nanocarriers for cancer therapy. Biomater Sci. 2015;3:955–987.
   PubMed Web of Science ®Google Scholar
• Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6:688–701.
   PubMed Web of Science ®Google Scholar
• Luo Y, Prestwich G. Cancer-targeted polymeric drugs. Curr Cancer Drug Targets. 2002;2:209–226.
   PubMed Web of Science ®Google Scholar
• Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst. 2003;20:357–403.
   PubMed Web of Science ®Google Scholar
• Yavuz MS, Cheng Y, Chen J, et al. Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nat Mater. 2009;8:935–939.
   PubMed Web of Science ®Google Scholar
• Sun Y, Li Y, Huang H, et al. PH-sensitive poly(itaconic acid)-poly(ethylene glycol)-poly(l-histidine) micelles for drug delivery. J Macromol Sci A Pure Appl Chem. 2015;52:925–933.
   Web of Science ®Google Scholar
• Mendes ANAN, Hubber I, Siqueira M, et al. Preparation and cytotoxicity of poly(methyl methacrylate) nanoparticles for drug encapsulation. Macromol Symp. 2012;319:34–40.
   Google Scholar
• Zhu RR, Qin LL, Wang M, et al. Preparation, characterization, and anti-tumor property of podophyllotoxin-loaded solid lipid nanoparticles. Nanotechnology. 2009;20:055702.
   PubMed Web of Science ®Google Scholar
• Wu LP, Ficker M, Christensen JB, et al. Dendrimers in medicine: therapeutic concepts and pharmaceutical challenges. Bioconjug Chem. 2015;26:1198–1211.
   PubMed Web of Science ®Google Scholar
• Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54:631–651.
   PubMed Web of Science ®Google Scholar
• Wang J, Fang X, Liang W. Pegylated phospholipid micelles induce endoplasmic reticulum-dependent apoptosis of cancer cells but not normal cells. ACS Nano. 2012;6:5018–5030.
   PubMed Web of Science ®Google Scholar
• Elzoghby AO, Samy WM, Elgindy NA. Protein-based nanocarriers as promising drug and gene delivery systems. J Control Release. 2012;161:38–49.
   PubMed Web of Science ®Google Scholar
• Kreuter J. Nanoparticles – a historical perspective. Int J Pharm. 2007;331:1–10.
   PubMed Web of Science ®Google Scholar
• Cajot S, Van Butsele K, Paillard A, et al. Smart nanocarriers for pH-triggered targeting and release of hydrophobic drugs. Acta Biomater. 2012;8:4215–4223.
   PubMed Web of Science ®Google Scholar
• Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today. 2010;15:842–850.
   PubMed Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615–1626.
   PubMed Web of Science ®Google Scholar
• Hirsjärvi S, Passirani C, Benoit J-P. Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol. 2011;8:188–196.
   PubMedGoogle Scholar
• Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989;49:4373–4384.
   PubMed Web of Science ®Google Scholar
• Swietach P, Vaughan-Jones RD, Harris AL, et al. The chemistry, physiology and pathology of pH in cancer. Philos Trans R Soc B Biol Sci. 2014;369:20130099–20130099.
   Web of Science ®Google Scholar
• Kato Y, Ozawa S, Miyamoto C, et al. Acidic extracellular microenvironment and cancer. Cancer Cell Int. 2013;13:89.
   PubMed Web of Science ®Google Scholar
• Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine. 2014;9:467–483.
   PubMed Web of Science ®Google Scholar
• Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s disease and Parkinson’s disease). J Drug Deliv. 2011;2011:1–12.
   Google Scholar
• Mendes AN, Filgueiras LA, Siqueira M, et al. Encapsulation of Piper cabralanum (Piperaceae) nonpolar extract in poly(methyl methacrylate) by miniemulsion and evaluation of increase in the effectiveness of antileukemic activity in K562 cells. Int J Nanomedicine. 2017;12:8363–8373.
   PubMed Web of Science ®Google Scholar
• Laginha KM, Verwoert S, Charrois GJR, et al. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res. 2005;11:6944–6949.
   PubMed Web of Science ®Google Scholar
• Charrois GJR, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta Biomembr. 2004;1663:167–177.
   PubMed Web of Science ®Google Scholar
• Chandrasekharan N, Kamat P. Improving the photoelectrochemical performance of nanostructured TiO2 films by adsorption of gold nanoparticles. J Phys Chem B. 2000;104:10851–10857.
   Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–7803.
   PubMed Web of Science ®Google Scholar
• Li Z, Qiu Y, Lu W, et al. Immunotherapeutic interventions of triple negative breast cancer. J Transl Med. 2018;16:147.
   PubMed Web of Science ®Google Scholar
• Cheung A, Bax HJ, Josephs DH, et al. Targeting folate receptor alpha for cancer treatment. Oncotarget. 2016;7:52553–52574.
   PubMedGoogle Scholar
• Ginter PS, McIntire PJ, Cui X, et al. Folate receptor alpha expression is associated with increased risk of recurrence in triple-negative breast cancer. Clin Breast Cancer. 2017;17:544–549.
   PubMed Web of Science ®Google Scholar
• Leone JP, Bhargava R, Theisen BK, et al. Expression of high affinity folate receptor in breast cancer brain metastasis. Oncotarget. 2015;6:30327–30333.
   PubMedGoogle Scholar
• Zhang Z, Wang J, Tacha DE, et al. Folate receptor alpha associated with triple-negative breast cancer and poor prognosis. Arch Pathol Lab Med. 2014;138:890–895.
   PubMed Web of Science ®Google Scholar
• Shi H, Guo J, Li C, et al. A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Des Devel Ther. 2015;9:4989–4996.
   PubMed Web of Science ®Google Scholar
• Yao N, Xiao W, Wang X, et al. Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method. J Med Chem. 2009;52:126–133.
   PubMed Web of Science ®Google Scholar
• Schiener M, Hossann M, Viola JR, et al. Nanomedicine-based strategies for treatment of atherosclerosis. Trends Mol Med. 2014;20:271–281.
   PubMed Web of Science ®Google Scholar
• Sutton D, Nasongkla N, Blanco E, et al. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res. 2007;24:1029–1046.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Hamaguchi T, Ura T, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer. 2004;91:1775–1781.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA. 2006;103:6315–6320.
   PubMed Web of Science ®Google Scholar
• Xiao K, Li Y, Lee JS, et al. “OA02” peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res. 2012;72:2100–2110.
   PubMed Web of Science ®Google Scholar
• Aina OH, Marik J, Gandour-Edwards R, et al. Near-infrared optical imaging of ovarian cancer xenografts with novel alpha 3-integrin binding peptide “OA02”. Mol Imaging. 2005;4:439–447.
   PubMedGoogle Scholar
• Xiao W, Luo J, Jain T, et al. Biodistribution and pharmacokinetics of a telodendrimer micellar paclitaxel nanoformulation in a mouse xenograft model of ovarian cancer. Int J Nanomedicine. 2012;7:1587–1597.
   PubMed Web of Science ®Google Scholar
• Calzolari A, Oliviero I, Deaglio S, et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis. 2007;39:82–91.
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Hekmatara T, Herbert E, et al. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB). Eur J Pharm Biopharm. 2009;71:251–256.
   PubMed Web of Science ®Google Scholar
• Fondell A, Edwards K, Unga J, et al. In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an 125I-labelled DNA-intercalator. J Drug Target. 2011;19:846–855.
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen J, Zheng Y, et al. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res. 2009;69:6506–6514.
   PubMed Web of Science ®Google Scholar
• Kim D, Gao ZG, Lee ES, et al. In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Mol Pharm. 2009;6:1353–1362.
   PubMed Web of Science ®Google Scholar
• Chaudhury A, Das S, Bunte RM, et al. Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft. Int J Nanomedicine. 2012;7:739–751.
   PubMed Web of Science ®Google Scholar
• Parrott JA, Doraiswamy V, Kim G, et al. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol. 2001;172:213–222.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jia L, Feng Y, et al. Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer. Cancer Lett. 2009;278:56–64.
   PubMed Web of Science ®Google Scholar
• Canney PA, Moore M, Wilkinson PM, et al. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer. 1984;50:765–769.
   PubMed Web of Science ®Google Scholar